Carl Icahn sees large returns on Biogen Idec and Genzyme bets

May 15th, 2011
| More
Carl Icahn, founder of hedge fund Icahn Associates, has made two very large investments in biotech since 2008. The first, Biogen Idec (NASDAQ: BIIB), began in 2008, when Icahn Associates bought about 12.9 million shares of Biogen Idec at $50.45 per share, or about a $650 million stake. Biogen Idec has advanced 46% year to date, and most recently was trading at around $98.10. This represents a $614 million gain on Mr. Icahn’s investment, or a 94% return.

According to the Boston Globe, when compared to the S&P 500, which has lost 8.3% in the same period, his investment seems like a stroke of genius. However, when compared to a benchmark biotech stock index tracking 20 leading biotech companies which has returned 90% in the period, Mr. Icahn’s returns seem much less impressive.

The story is the same with Genzyme (NASDAQ: GENZ). Mr. Icahn spent about $562 million to purchase around 10.5 million shares of Genzyme. When Genzyme sold itself to Sanofi-Aventis for $20.1 billion, or $76.25 per share, Mr. Icahn profited about $237 million, a gain of 42%. However, when compared to the biotech index, which gained 47.5% in the period, Mr. Icahn’s trades seem relatively pedestrian.
See Source
For Detailed Investor Profiles on these Investors, click below:
Icahn Associates (Carl Icahn)
Related People: Alexander J. Denner; Brett Icahn; Carl Icahn; Keith A. Meister*
Related Entities: High River Limited Partnership; Icahn Partners; Icahn & Co Inc; Icahn Associates; Icahn Enterprises (formerly American Real Estate Partners); Icahn Fund Ltd; Icahn Partners LP
Related Article Tags: Multi-Strategy, Long Short, Equity, Debt and Global Macro Hedge Fund News


More Recent Headlines

John Paulson set to earn up to 78% return on investment in Lehman Brothers bonds

Daniel Chan, Former Citi Portfolio Manager, Launches Emerald Orient Investment Advisor with $25M

Renaissance Technologies’ troubled hedge funds experience Resurgence in 2011

Top Hedge Fund List sees Assets jump by 24% in 2010

David Tepper seeds Matthew Knauer’s Nokota Management

Citadel Investment Group recruits Jamil Nazarali and Matt Cushman to launch Quantitative Trading Business

Och-Ziff Capital Management Announces Q1 2011 Results

Affiliate of Credit Suisse Acquires Minority Stake in Lucidus Capital Partners

Millbrook Capital Management Demands that EMS Technologies Speed Up its Sale

Kenneth Griffin’s Citadel Investment Group further reduces E*Trade Financial Corp stake